January 16, 2019 / 12:03 PM / 9 months ago

BRIEF-Newron Pharmaceuticals: Commercialization Partner Zambon With Valeo Pharma Announce Approval Of Onstryv® (Safinamide) For Parkinson’S Disease In Canada

Jan 16 (Reuters) - NEWRON PHARMACEUTICALS SPA:

* NEWRON PHARMACEUTICALS: COMMERCIALIZATION PARTNER ZAMBON TOGETHER WITH VALEO PHARMA ANNOUNCE THE APPROVAL OF ONSTRYV® (SAFINAMIDE) FOR PARKINSON’S DISEASE IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below